Langston University

Digital Commons @ Langston University
McCabe Thesis Collection

Student Works

5-2003

Photodynamic Therapy
Ashley Thomas

Follow this and additional works at: http://dclu.langston.edu/mccabe_theses
Part of the Biology Commons, Cell and Developmental Biology Commons, Diseases Commons,
Oncology Commons, and the Osteopathic Medicine and Osteopathy Commons
Recommended Citation
Thomas, Ashley, "Photodynamic Therapy" (2003). McCabe Thesis Collection. Paper 13.

This Thesis is brought to you for free and open access by the Student Works at Digital Commons @ Langston University. It has been accepted for
inclusion in McCabe Thesis Collection by an authorized administrator of Digital Commons @ Langston University. For more information, please
contact jblewis@langston.edu.

The Edwin P. McCabe Honors Program
Senior Thesis

"Photodynamic Therapy"

Ashley Thomas
May 2003

Langston University
Langston, Oklahoma

Photodynamic Therapy
...
ff(,aL.

Thesis Approved:

/

Center

-

..

~hesis 7 ommittee Chairman

Thesis Committee Member

Dr. Sarah Thomas (deceased)
Thesis Committee Member

/

Dean of the Honors Program

J'

Vice' President of Acade1 Affairs

ACKNOWLEDGMENTS

I wish to send out a personal thanks to Dr. Sonya
Williams, my chairman, for her never-ending support, honesty,
and outstanding supervision. I would also like to say thank you
for all of the after hours you have put into me in helping shape
me into the scholar I am today. I would also like to thank Dr.
John Coleman for advising me when I need it the most. Thank
you for the humor you gave me which allowed me to get threw
the day and this project. Without it, I do not know where I
would be.
I would also like to send a special thank you to Dr.
Lucroy and his team for allowing me to work in the laboratory
on this scintillating internship. I truly expanded my knowledge
base, as well as myself in the months that I was granted to work
on this project with him. I would also like to thank Oklahoma
State University for allowing me to come into Dr. Lucroy's
laboratory for the summer.

Table of Contents
Chapter

Page

I.

INTRODUCTION
Introduction .............................................. 1
Background ............................................... 2
Objectives of Study .................................... .4
Definition of Terms ..................................... 5
Outline of Work ......................................... 9

II.

LITERATURE OF REVIEW
History of Photodynamic Therapy ................... 10
How Photodynamic Therapy Works ................. 12
Selectivity of Tumor Localization of
Photosensi tizers ......................................... 12
How Laser Light is Delivered to Tumor ............ 13
Why Photodynamic Therapy works within the
tumor ...................................................... 15
The Application of Photodynamic Therapy in
Veterinary Medicine .................................... 17
Hematoporoohyrin Photosensitizers .................. 17
Aluminum Phalocyanine Tetrasulfonate ............. 19
Pheophorbide Photosensitizer .......................... 20

III.

METHODOLGY
Chapter Overview ........................................ 23
Research Methodology .................................. 24
Preparation of Media .................................... 24
Growing of K-9 Bladder Cancer Cells ................ 26
Detaching of the K-9 Bladder Cancer Cells .......... 27
Cell Count. ............................................... 29
Plating of the K-9 Bladder Cancer Cells .............. 31
Cell Control ............................................... 31
Cell Plating for the Rest of The Experiment. ........ 32
Treating the K-9 Bladder Cancer Cells
with HPPH ................................................ 33

Treating the K-9 Bladder Cancer Cells
with Lasers ................................................ 34
Dye Laser .................................................. 35
Luma Care Laser .......................................... 36
Treating the K-9 Bladder Cancer Cells with Protien
Treatment .................................................. 37
Running the K-9 Bladder Cancer Cells through the
Floresence Light Reader ................................. 39
IV.

RESULT AND DISCUSSION
Results of Study .......................................... 41

V.

SUMMARY AND CONCLUSION
Summary ...................................................42
Cone Ius ion ................................................ 43

List of Figures
Rgure

P~

1.

Drug Concentration ..................................44

2.

Exposure Time .................... .................. .45

3.

Light Intensity ...................................... .46

Nomenclature

PDT

Photodynamic Therapy

PBS

Phosphate Buffered Saline

TCA

Trichloroacetic Acid

HAc

Acedic Acid

SRB

Sulfarhodamine B

FBS

Fetal Bovine Syrum

HPPH

Photosynthesizing drug -2-[ 1hexy loxyethy 1]-2-di viny 1 pyropheophorbidea
Aluminum phthalocyanine tetrasulfonate

K-9

Canine as referred to a dog
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CHAPTER I

INTRODUCTION
1.1 Introduction
Photodynamic therapy is a new treatment that is being
introduced into the veterinary community. Photodynamic
therapy is the use of light activated chemotherapy to kill
cancer cells (Dougherty, 1998). It has already been
approved by the US Food and Drug Administration to be
used as a form of cancer treatment in humans, but has not
been carried over to the veterinary community. That is until
now. Photodynamic therapy is now being tested in the
veterinary community in hopes to find the same results that
the human medical community has when dealing with
certain types of cancer. They also hope to permanently
adopt the new procedure into facilities as an alternative
form of cancer treatment.
1

1.2 Background
Photodynamic therapy, also known as light activated
chemotherapy and photochemotherapy, is a method of
cancer treatment that has recently been approved by the US
Food and Drug Administration for curative treatment of
early-stage lung cancer and palliative treatment in humans
(Dougherty, 1998). Since it has not been adopted into the
veterinary medical community, veterinarians have no idea
how the PDT will work on the animal species. Trials are
now being done to see if veterinarians will get the same
results as the medical doctors have and if they do, if the
results will show that it would be worth using PDT
permanently as an alternative form of cancer treatment.
They are also concerned with how it will effect the cancer
in the animal, what the side effects will be to the animal,
what type of photosensitizer to use, what concentration of
the photosensitizer to use, how long exposure time should
be, and what laser intensity should be used. These are all
2

things that the veterinarian community has taken into
consideration and are now running trials, like the one done
in this paper, to see what the outcome will be (Lucroy,

2000).

3

1.3 Objective of Study
To see if the Dye laser or the Luma Care laser yields the
highest percent kill of the K-9 bladder caner cells. To see
what drug concentration, light intensity, and length of
exposure time yields the best percent kill in regards to each
of the lasers.
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1.4 Definition of Terms
Media- The substance in which a specific organism lives
and thrives.
Cancer cell- A cell that is part of a malignant tumor.
Carsinoma- An invasive malignant tumor derived from
epithelial tissue that tends to metastasize to other areas of
the body.
Antimycotic- Antibiotic
Hemacytometer- An instrument for counting the number
of blood cells in a measured volume of blood.
Trypsin- A pancreatic enzyme that catalyzes the
hydrolysis of proteins to form smaller polypeptide units.
Florescence Light Reader- An instrument used to read
the amount of Ultraviolet Light that is emitted through
cells.
Rocker Platform- An instrument that is used to mix
substances by using a continuous rocking motion.
Necrosis- Death of cells or tissues through injury or
disease, especially in a localized area of the body.
Neoplastic tissue- An abnormal new growth of tissue in
animals or plants; a tumor.
Osteosarcomas- A malignant bone tumor. Also called
osteogenic sarcoma.
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Cutaneous- Of, relating to, or affecting the skin.
Photosensitization- Sensitization of the skin to light,
usually due to the action of certain drugs, plants, or other
substances; may occur shortly after administration of the
drug (phototoxic sensitivity), or may occur only after a
latent period of from days to months.
Erythema- Redness of the skin caused by dilatation and
congestion of the capillaries, often a sign of inflammation
or infection.
Sloughing- A layer or mass of dead tissue separated
from surrounding living tissue, as in a wound, sore, or
inflammation.
Hyperthermia- Unusually high body temperature.
Pharmacokinetics- The process by which a drug is
absorbed, distributed, metabolized, and eliminated by the
body.
Thrombosis- The formation or presence of a thrombus (a
clot of coagulated blood attached at the site of its
formation).
Apoptosis- Cell death
Lesions- A localized pathological change in a bodily
organ or tissue.
Squamous- Resembling a scale or scales; thin and flat
like a scale.
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Malignant- Characterized by progressive and
uncontrolled growth (especially of a tumor).

Melanoma- A dark-pigmented, usually malignant tumor
arising from a melanocyte and occurring most commonly
in the skin.
Mast Cell- A cell found in connective tissue that
contains numerous basophilic granules and releases
substances such as heparin and histamine in response to
injury or inflammation of bodily tissues.
Tumor- An abnormal growth of tissue resulting from
uncontrolled, progressive multiplication of cells and
serving no physiological function; a
neoplasm.
Fibrosarcoma- Malignant tumor derived from
connective tissue fibroblast.
Sebaceous- Secreting fat or sebum.
Metastatic- Transmission of pathogenic microorganisms
or cancerous cells from an original site to one or more
sites elsewhere in the body, usually by way of the blood
vessels or lymphatics.
Prostatic- Of or pertaining to the prostate gland.
Morbidity- The rate of incidence of a disease.
Inappetence- Lack of appetite.
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Planum Nasale- Hat plane of the nasal.
Pinnae- The auricle of the ear.
Eschar- A dry slough, crust, or scab, which separates
from the healthy part of the body, as that produced by a
burn, or the application of caustics.
Emesis- The act of vomiting.
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1.5 Outline of Work
The bulk of the paper will be based on the methodology
that was used in the experiment.

9

CHAPTER II

REVIEW OF THE LITERATURE

2.1 History of Photodynamic Therapy
One of the oldest known methods for using light
treatment to treat disease is found in the ancient Vedic text

Atharva-Veda, circa 1400 B.C. It tells about the use of certain
plant seeds and sunlight to treat vitiligo (Daniell, 1991). In
1903, the Nobel Prize was given to Danish scientist Niels
Finsen for using light and eosin to treat lupus vulgaris (Daniell,
1991). In the same year, Herman von Tappeiner coined the
phrase "photodynamic therapy" to describe the oxygendependent therapy he discovered when working with light
reactions (Jesionek, 1903).
In 1911, hematoporphyrin was discovered to have
photosynthesizing properties that could be used to activate
10

photodynamic agents in vitro against agents such as

Plasmodium falciparum, the causative agent in human malaria
(Hausman, 1911).
Further development in this area did not occur until the
mid twentieth century. In the mid twentieth century, Schwartz,
Winkelman, and Lipson discovered that fluorescence of
photosynthesizes like hematoporphyrin could detect tumors
(Dougherty, 1992). It was observed that hematoporphyrin
accumulated in tumors after systemic administration to rats and
that upon illumination, caused tumor necrosis (Figge, 1948).
Since then, the studies that surround this new form of treatment
has intensified with a host of clinical PDT applications. During
the last 25 years, thousands of human patients have been treated
by PDT with outstanding results.

11

2.2 How Photodynamic Therapy Works
2.2.1 Selectivity of tumor localization of photosensitizers
For photodynamic therapy to be effective, the
photosensitizer must selectively localize in neoplastic tissue
(Lucroy, 2000). The mechanisms involved in the localization
of photosensitizers to tumors are poorly understood, however;
the characteristics of the tumor, photosensitizer, and how they
are delivered are clearly understood and may play a role in how
the photosensitizer reaches its location (Lucroy, 2000). An
example of this would be how porphyrins bind to new collagen
fibers to be taken into the tumor (Musser 1980).
Localization of photosensitizers to tumor tissue increases
as the degree of drug hydrophobicity increases (Kessel 1990).
By incorporating photosensitizers into the liposomes or
amphiphilic systems, it may increase the photosensitizers
uptake into the tumors (Jori, 1996). It appears that
photosensitizers with lipoproteins with low densities seem to
12

release to tumor cells (Allison, 1990). It also appears that the
lower the pH of the tumor cell, the increase in the lipoproteins
and cellular uptake of the photosensitizer into the tumor
(Barrett, 1990). The ideal photosensitizer for the PDT
treatment would not have any systemic toxicity, it would be
selectively taken up by the tumor and retained there instead of
being taken up by the tumor and the surrounding healthy tissue
(Lucroy, 2000). A number of photosensitizers have been used
in the veterinary medical community, but only Photofrin has
been approved by the FDA to be used in humans
(Dougherty, 1998).
2.2.2 How laser light is delivered to tumor
The amount of light wavelength required for the PDT
therapy depends upon what photosensitizer that is being used
(Lucroy, 2000). Also, how the light will penetrate the tissue is
directly related to the wavelength of laser light used (Wilson,
1985). The laser light can be delivered to the tumor by a
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number of ways. They include to the surface, interstitial, or
intraoperative irradiation (Lucroy, 2000). The light is focused
on the tumor by an optical fiber that has a microlens at the end.
The optical fibers can be placed directly into the tumor for
interstitial irradiation by the addition of a cylindrical diffusion
tip. Optical fibers can also be used in the gastrointestinal tract
and urinary bladder by the specialized fibers with a flexible
endoscope (Lucroy, 2000).
The amount of light dose delivered can be expressed in
fluence and power density (Grossweiner, 1997). Fluence is the
amount of light (number of photons) delivered to a given area
and is expressed as joules per square centimeter (Lucroy, 2000).
Power density is the rate (number of photons per unit time) at
which light is delivered to a given area and is expressed as
watts per square centimeter (Lucroy, 2000). The power density
and fluence both have an effect on how efficient the PDT
therapy will be. The lower the power densities are associated
with higher local tumor control rates and more efficient tumor
14

killing (Moor, 1997).
2.2.3 Why PDT works within the tumor
PDT works well in the killing of tumors due to three
mechanisms. The first mechanism is PDT may directly damage
tumor cells (Lucroy, 2000). Secondly, PDT induced oxidative
damage to tumor vasculature may result in stasis of blood flow,
vascular leakage, and thrombosis formation with tumor death
(Henderson, 1994). Thirdly, PDT may cause release of
cytokines and other inflammatory mediators from treated cells,
which is followed by nonspecific tumor cell killing resulting
from the rapid flux of neutrophils and other inflammatory cells
(Korbelik 1996).
After examination of the tumors that underwent the PDT
treatment necrosis and apoptosis occurred in the tumor (Zaidi,
1993). These findings are very important because when a cell
becomes malignant, it loses its ability to undergo apoptosis.
This loss of ability is what causes the cells resistancy to

15

ionizing radiation and other antineoplastic drugs (Lucroy,
2000). It is not certain why PDT seems to trigger the apoptosis
in the tumors. Studies are being done to try to find the answer
to this question.

16

2.3 The Application of Photodynamic Therapy in
Veterinary Medicine.
The application of PDT into the veterinary medical
community is new. Photodynamic therapy is still being used in
the experimental stages with various photosensitizers to see
which photosensitizers work the best with the patient and with
the cancer type. The following are a list of a few of the
photosensitizers being used today and what the outcomes were.

2.3. l Hematoporphyrin photosensitizers
Hematoporphyrin photosensitizer and light have
been used to treat a variety of tumors in 8 dogs and 3 cats
(Dougherty, 1981 ). The tumors that were treated in this
experiment included osteosarcoma, squamous cell
carcinoma, malignant melanoma, mast cell tumor,
fibrosarcoma, sebaceous gland tumor, and metastatic
prostatic carcinoma. The animals were given the
Hematoporphyrin photosensitizer 48 hours before light
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treatment. The light source used was an argon-pumped
dye laser with a spectral output of 635 nm was delivered
through a 200 µm quartz fiber optics inserted into the
tumors l .5-2cm apart, depending on tumor size.
Treatment times varied from 20-30 minutes, power
intensities ranged from 120-900 mW/cm2 • Of the 14
lesions, 12 (86%) were considered responsive. The two
lesions that were not responsive were the Osteosarcomas
(Lucroy, 2000).
In another study, the tumor that was localized
fraction of the Hematoporphyrin photosensitizer was
used for PDT of 25 naturally occurring tumors in 14 dogs
and 6 cats (Cheli, 1987). The animals were given
Photofrin II and treated with 631 nm laser light 48 hours
later. By using external light application, 23 tumors were
treated. One of the 23 tumors was treated by
intracavitary irradiation, using a flexible endoscope, and
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1 was treated by interstitial light application. Five of
those tumors were reduced surgically before PDT was
applied. The power density ranged from 85-1,000
mW/cm2 with fluences of 66-960 J/cm2 • A follow-up
was done 6-14 months later. The results were that a
complete remission was reported for 4 of the 5 tumors
that were surgically reduced prior to the PDT treatment
and for 5 of 8 tumors treated with the PDT treatment
alone. The outcome for the rest of the tumors was not
reported (Cheli, 1987).

2.3.2 Aluminum phtalocyanine tetrasulfonate
Aluminum phtalocyanine tetrasulfonate (AlPcS 4)
is used as a photosensitizer with the PDT treatment ot
cats with solar-included squamous cell carcinoma of the
planum nasale and pinnae (Peaston 1993). Eighteen cats
were used in this study. Within the 18 cats, there were
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19 lesions present. The 19 lesions were treated with
AlPcS 4 and treated 24 hours later with light from and
argon-pumped dye laser at 675 nm delivered with an
optical quartz fiber fitted with a microlens. The power
intensity was 100 mW/cm 2 , fluence was 100 J/cm2 and
treatment time was 16 minutes 40 seconds for each cat
(Peaston 1993). The results were associated with the
drug admission itself; complete responses were
approximately 70% of the animals. The adverse effects
included local, self-limiting tissue swelling, inappetence,
and eschar formation (Peaston 1993).
2.3.3 Pheophorbide photosensitizer
The photosensitizer known as 2-[l-hexyloxyethyl]2-diviny-pyropheophorbide-a (HPPH) is now being used
in clinical trials in veterinary medicine.

The first

published use of HPPH for veterinary PDT was on 61
cats with naturally occurring squamous cell carcinoma of
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the planum nasale, pinnae, and facial skin (Mange 1997).
Each cat was treated with HPPH 24 hours before light
irradiation with a wavelength of 665 nm was delivered
through an optical quartz fiber optic fitted with a
microlens. The power intensity used was 75 m W/cm2
and fluence was 100 J/cm 2 • The results of this study
were that there was a I 00% response rate for superficial
tumors < 1.5 cm in diameter and an 18% for invasive
tumors > 1.5 cm in diameter. The adverse effects were
not shown to be with the administration of the drug itself,
but substantial morbidity was observed in several cats
after the PDT treatment (Mange 1997). Other adverse
effects included erythema, and edema in and around the
treated are lasting only 3-5 days after treatment. Five of
the cats that had large lesions developed a cardiac
decompensation syndrome manifest as acute congestive
heart failure (Mange 1997).

21

Another study done using HPPH was done in dogs
that had hemangiopericytoma and oral squamous cell
carcinoma. Each dog was given HPPH 48 hours before
they

were

with

treated

light

therapy.

Hemangiopericytoma was surgically removed and tumor
bed and a margin of grossly normal tissue were
irradiated.

Squamous cell carcinoma was surgically

reduced prior to PDT treatment but only if they were > .5
cm thick. The laser light was delivered at 665 nm with a
quartz fiber optic fitted with a microlens and fluence was
100 J/cm2 •

The results were that the 11 dogs with

hemangiopericytomas

were

considered

to

have

a

complete response to the treatment with a follow-up time
of 5.3 months. Four of the 5 dogs with oral squamous
cell carcinomas were considered to have a complete
response with a follow-up time of 10.4 weeks. The only
adverse effect consisted of edema in treated area.

22

CHAPTER III

METHODOLOGY

3.1 Chapter Overview

This chapter is used to describe each method and what was
used in the experiment. There was a lot of microbiological
and general lab techniques used in this experiment. Each
procedure was performed at Oklahoma State University in
the Microbiology laboratory. The procedures were either
performed by me, Dr. Lucroy, or Trisha Ridgeway. Each
Procedure has its own explanation and is basically the body
of the thesis.

23

3.2 Research Methodology

The first thing that was done in the laboratory was the
preparation of the media so that the K-9 bladder cancer
cells could grow. The K-9 bladder cancer cells came to us
in the laboratory from a commercial dealer. They were
stored in liquid nitrogen until we were ready to use them.

3.2.1 Preparation of the Media
We first made the media by adding L-glutamine,
Fetal Bovine Syrum, and Antimycotic to a 500ml flask.
We then brought the volume up to 500ml by adding
RPMI-1640 by using suction filtration to filter out
impurities. This media is used to feed the cells. After we
were done with media we stored it in the refrigerator
until later use. Media will last about two weeks.

24

Reagents and Supplies
Amount
L-glutamine

10 ml

Fetal Bovine Syrum

50ml

Antimycotic

5ml

RPMI-1640

435 ml

-Pipetted all of these substances into the 500 ml Flask.
-Used suction filtration to add the RPMI-1640 to flask.
-Added this media to the cells to aid in growth of cells.
-Kept media in a refrigerator.
-Kept cells in an incubator set at 37 degrees Celsius.
-500 ml Flask
-Suction filtration apparatus.
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3.2.2 Growing of the K-9 Bladder Cancer Cells
The commercially ordered K-9 Bladder Cancer
cells were stored in a liquid nitrogen tank until we
needed them. When we needed a fresh sample of cells,
we would take the micropipette vile out of the liquid
nitrogen and place it in a warm water bath so they could
defrost. We then took a pipette and sucked out the fresh
K-9 bladder cancer cells and added them to 15 ml of
media, mixed the solution together, and placed in
incubator at 37 degrees Celsius to grow cells. We
checked the growth of the cells each day and changed the
media daily as well. When the bottom of the flask was
covered with cells, we then were ready to detach them
from the bottom of flask, do our cell count, and plate the
cells.
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Reagents and Supplies
Amount
Commercially ordered Cells

2 ml

Media

15 ml

-Incubated cells at 37 degrees Celsius to grow cells.
-Changed the media daily.
-Flask

250ml

-Liquid nitrogen tank (cell storage unit)

3.2.3 Detaching of the K-9 Bladder Cancer Cells
After the cells had spread across the bottom of the
250 ml flask, it was time to detach the cells and prepare
them for cell counting and cell plating. The first step to
detaching the cells is to suck off the old media and rinse
the cells twice with a Phosphate Buffered Solution. After
sucking off the PBS, we added Trypsin to the flask. We
then set the cells back into the incubator for
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approximately 5 minutes. We then added media to
neutralize the Trypsin and mixed the two mixtures
together well to insure that neutralization had taken
place. We then used this neutralized solution to take a
cell count.

Reagents and Supplies
Amount

Phosphate Buffered Solution

15 ml

Trypsin

4ml

Media

5 ml

-Warmed the PBS, Media, and Trypsin in a warm water
bath for approximately I 0 minutes.
-Added 15ml of PBS twice to rinse the cells.
-Used suction filtration to remove the PBS and Media
from cells.
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-Used pipettes to add the PBS, Media, and Trypsin to
flask.
-Incubated Trypsin on cells at 37 degrees Celsius for 5
minutes.

3.2.4 Cell Counting

After the cells have been detached and the Trypsin
neutralized, we take two small drops of the solution and
placed one drop on each side of the slide or
hemacytometer. We then placed the cover slip onto the
slide and placed it under a microscope to count how
many cells are in the four quadrants. After we found out
how many cells are in each of the quadrants, we then
added all of the quadrants together to get a total number
of cells in flask. We then took that total number and ran
it through a series of calculations to find out how much
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media we needed to add to the cell solution so we could
plate 20,000 cells per plate.

Reagents and Supplies
Amount
Microscope
2 small drops

Cell solution

Calculation
Here is an example of how the calculation was used.
Upper left quadrant-150 cells
Lower left quadrant-251 cells
Upper right quadrant-276 cells
Lower right quadrant-227 cells
Total cells: 904 cells

4
226 (average# cells)
xl0.000
2,260,000 (cells/milliliter)
x8
18,080,000(total cells in flask)
+100.000
I 80.8 ml (media needed to be
added to flask of cell solution so cells can be plated
20,000 cells per plate)
+
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3.2.5 Plating of the K-9 Bladder Cancer Cells
3.2.5. l

Cell Control
Before treating the cells with the lasers or drug, we

first needed a control to go by. We got this control by
taking the cells we grew and counted and did various cell
concentrations in the petri dishes. We did 6 petri dishes
with various amounts of cells in them. Incubated them
overnight, ran them through protein treatment, and then
through the Florescence light reader to get amount of
light emitted threw the cells.

Reagents and Supplies
Amount
.5 ml cells solution and
1.5 ml of media

50,000 cells per plate

25,000 cells per plate

.25 ml cell solution and
l.75ml of media

12,500 cells per plate

.125 ml cell solution and
1.85 ml of media

6,250 cells per plate

.06 ml of cell solution
and 2.0 ml of media
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3,125 cells per plate

.03 ml of cell solution
and 2.0 ml of media

1,563 cells per plate

.03 ml of cell solution
and 2.0 ml of media

3.2.5.2

Cell Plating for Rest of Experiments
This stage was done by running a fresh group of
cells through the same calculation above, but this time
we used a set amount of cells per plate in regards to
the rest of the experiments. The cell amount was as
followed.

Reagents and Supplies
Amount
20 µl of cell
solution and 2.0 ml of
media

20,000 cells per plate
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3.2.6 Treating the K-9 Bladder Cancer Cells with HPPH
We took the fresh group of cells that were plated
20,000 cells per plate and plated 30 plates of 20,000 cells
per plate. With these 30 plates, we added different
concentrations of the HPPH drug to them. We got the
HPPH drug dilution by taking two small flasks, one with
2 ml of media and the other with 4 ml of media, and
adding .2cc of HPPH to the 2ml flask. We then took the
2 ml flask of media and of .2cc of HPPH and mixed it
with the 4 ml flask of media. We then took the drug
amounts out of the 4ml flask. We then incubated plates
overnight to prepare them to be run with the laser
treatment and then through the Florescence light reader
to see what drug concentration had the highest percent
kill of the cancer cells. The 30 plates and their HPPH
concentrations are as followed.
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Reagents and Supplies
Amount
6 plates with 0 amount of drug

OHPPH

6 plates with .25 amount of drug

20µ1 HPPH

6 plates with .5 amount of drug

40µ1 HPPH

6 plates with 1.0 amount of drug

80µ1 HPPH

6 plates with 2.0 amount of drug

160µ1 HPPH

-Incubated plates at 37 degrees Celsius overnight to
prepare cells for laser treatment.
-We used a constant of 40 µI of HPPH to treat all of the
next experiments.

3.2.7 Treating the K-9 Bladder Cancer Cells with Lasers
We used two different lasers in treating the K-9
Bladder caner cells, the Luma Care laser and a Dye laser.
The Luma Care laser was ran by a specially made light
bulb, which is what was used to treat the plated K-9
caner cells. The Dye laser was a lot bigger apparatus that
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uses a combination of Argon gas with a quartz wire to
treat the plated K-9 cancer cells. This laser could treat 3
plates at a time whereas the Luma Care laser could only
treat I plate at a time.

3.2.7.1

Dye Laser
The Dye Laser treated the different plates with
various amounts of intensities at first. After the plates
were treated, they were treated with the protein
treatment and then ran through the florescence light
reader to determine what laser intensity was the best.
That was determined by seeing what laser intensity
was yielding the highest percent kill. The intensities
on the first experiment varied. They are as stated
below.
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Reagents and Supplies
Power density
30
20
10

Milliwatts
2.36
1.6
785

0

0

Time
8 min.
I 2.5min
25 min
Omin

-Dye Laser that was stored in the laboratory was used in this
experiment.
-After exposure to laser, the cells had new media placed on
them and then stored back into the incubator at 37 degrees
Celsius until the next day when protein treatment was ran.

3.2.7.2

Luma Care Laser
The Luma Care laser treated the different plates
with various amounts of intensities at first. After the
plates were treated, they were treated with the protein
treatment and then ran through the florescence light
reader to determine what laser intensity was the best.
That was determined by seeing what laser intensity
was yielding the highest percent kill. The intensities
on the first experiment varied. They are as stated
below.
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Reagents and Supplies
Power density
30

Milliwatts
300

20

192-200

10

96-100

0

0

Time
8min
12.5min
25min
Omin

-Luma Care laser was stored in laboratory until it was ready to
use.
- After exposure to laser, the cells had new media placed on
them and then stored back into the incubator at 37 degrees
Celsius until the next day when protein treatment was ran.

3.2.8 Treating the K-9 Bladder Cancer Cells with Protein
Treatment
After the lasers were ran on the cells, they were
prepared to go through the Florescence light reader. In
order for us to get a good reading, the treated cells had to
be treated with various proteins so that the light that the
Florescence light reader gave off could emit through cells
properly. These reagents were already made when it was
time for us to use them. The first thing we did was to
suck off the old media by using suction filtration. We
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then washed the cells with the PBS and sucked that off
by suction filtration as well. We then added TCA and
placed them into the refrigerator for 20 minutes. We then
removed the TCA by suction filtration and washed cells
with HAc. We then removed the HAc by suction
filtration and added SRB and incubated at room
temperature for 20-30 minutes. After incubation was
complete we removed the SRB by suction filtration and
washed 3 times with HAc. We then let trays air dry out
of direct light for about 30 minutes. After they were dry,
we added Tris-Base and placed the cells in their petri
dishes on the rocker platform for 10 minutes. After 10
minutes, we took the plated cells off of rocker platform
and pipetted 1ml of them into a 96 well plate. This plate
was then placed into the Florescence light reader to be
read.
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Reagents and Supplies
Amount
PBS
lml
TCA
lml
lml
HAc
lml
SRB
HAc
I ml(3times)
lml
Tris-Base
-Placed 1ml of final solution (after the plated cells got off
the rocker platform) into a 96 well plate
-The second HAc was used after treatment with SRB

3.2.9 Running the K-9 Bladder Cancer Cells through the
Florescence IJght Reader
After the plated cells were ran through the protein
treatment, they were placed into a 96 well plate. This
plate goes inside of the Florescence light reader. This
plate holds the substances that the florescence light will
be emitted through to give the percent of how much light
was allowed to travel through cells. The principal behind
this is that the more light that is allowed to pass through
the plated cells, the lower the percent kill. The killed
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cells will adhere themselves to the plate, not allowing as
much light to travel through. We set the machine to run
550 nm of light through the plated cells each time it was
used. After the machine was ran, we compiled the data
that it gave us and placed that data on a graph to show
what drug concentration, laser intensity, and laser
exposure time gave us the greatest percent kill.
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CHAPTER IV

FINDINGS

4.1 Results of Study
By using .5 ml of the HPPH drug and 192-200 milliwatts
of power that it gave us the highest percent kill for the Luma
Care laser.
By using .5 ml of the HPPH drug, using 1.6 Watts of
power, and exposing the cancer cells for 666 seconds that this
combination yielded the highest percent kill of the cancer cells
with the Dye Laser.
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CHAPTERV

SUMMARY AND CONCLUSION

5.1 Summary
We found that by experiments we did that by using .5 ml
of the HPPH drug and 192-200 milliwatts ot power that it gave
us the highest percent kill for the Luma Care laser. However;
we are not sure what the correct length of laser exposure time
would be to give us the highest kill with this combination
above.
We found that by experiments we did that by using .5 ml
ot the HPPH drug, using 1.6 Watts of power, and exposing the
cancer cells for 666 seconds that this combination yielded the
highest percent kill of the cancer cells with the Dye Laser.
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5.2 Conclusion
If time had permitted, we would of went back and seen if

doubling the drug concentration on the experiment with the
different time trials if there would have been initial killing on
the Luma Care laser instead of initial growth.
All in all, this procedure seems to be promising for the
Veterinary community.
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Results
• Different drug concentrations.
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